IRON DEPOSITS BY NUCLEAR RESONANCE SCATTERING

在地中海贫血患者中，既增加了铁的营养吸收，又反复出现 输血会导致铁超载。这些铁矿床可能赋存于 身体中的许多器官和组织对人体产生有害影响 病人健康。在改善临床管理的研究中 对于重型地中海贫血，通过螯合疗法减轻铁负荷的方法 正在接受调查。这些研究因缺乏数据而受到阻碍 对体内储存的铁的灵敏定量测量。以下是 Proposal提供了一种独特的铁的定量、非侵入性测量方法 在上述螯合治疗计划中应用的存款，以便 对其有效性进行量化评估。 体内铁储存量的量化依赖于一种新开发的 核共振散射技术。在这项技术中，细胞核 的(92%的同位素丰度)被提高到它的第一激发态 伽马辐射。激发核衰变到基态通过发射 847keV伽马射线。这种伽马射线是通过特殊探测来测量的。 仪器仪表。 在最初的三年中，患者照射设施是 敏感度不断提高。这个原型设施是 由独立的砖块和钨条建造，被一块不锈钢取代 专为容纳可更换容器而设计的钢制矩形容器 准直器和一次性炉子。肝脏和肝脏中的铁含量 28例地中海贫血和4例铁血色沉着症患者的心脏 到目前为止，已经测量到了超载。 在下一阶段，这一设施将用于测量铁的变化 地中海贫血患者和含铁血黄素沉着症患者的沉积物 目前正在接受螯合治疗的血色素沉着症。具体的 有待回答的问题是，目前的螯合疗法 有效稳定或减少铁在心脏和肝脏中的储存 依赖输血的铁超载患者。

In Thalassemia, both increased iron alimentary absorption and repeated transfusions can cause iron overload. These iron deposits may occur in many organs and tissues in the body with deleterious effects on the patients health. In the research leading to improved clinical management of Thalassemia major, methods of reducing iron burdens by chelation therapy are being investigated. These studies have been hampered by the lack of sensitive quantitative measure of body stores of iron. The following proposal offers a unique quantitative, non-invasive measure of iron deposits to be applied in the above chelation therapy programs in order to evaluate quantitatively their effectiveness. The quantification of body stores of iron rests on a newly developed technique of nuclear resonance scattering. In this technique, the nucleus of 56Fe (92% isotopic abundance) is raised to its first excited state by gamma radiation. The excited nucleus decays to ground state by emission of the 847 KeV gamma-ray. This gamma ray is measured by special detection instrumentation. During the initial three years the patient irradiation facility was continually improved in sensitivity. The prototype facility which was built from separate bricks and tungsten bars, was replaced by a stainless steel rectangular container designed specially to accommodate exchangeable collimators and disposable furnaces. The iron content of the liver and heart of 28 Thalassemic patients and 4 patients with hemochromatosis iron overloads have been measured, to date. In the next phase, this facility will be used to measure changes in iron deposits in Thalassemic patients and patients with hemosiderosis and hemochromatosis currently undergoing chelation therapy. The specific question to be answered is whether the current chelation therapy effectively stabilizes or reduces iron stores in the heart and liver of transfusion dependent iron overloaded patients.